Tirzepatide

At a Glance

Molecular Properties

Overview

Compound Description

Tirzepatide is a synthetic 39-amino-acid peptide designed as a dual agonist that selectively binds and activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. The molecule incorporates two alpha-aminoisobutyric acid (Aib) residues at positions 2 and 13 for protease resistance, a C-terminal amide, and a C20 fatty diacid moiety conjugated at Lys20 that enables albumin binding and extends half-life. It has been the subject of extensive clinical trial programs including SURPASS and SURMOUNT.

Mechanism of Action

Research-Identified Pathways

Key Research Findings

Published Study Highlights

• SURPASS clinical trial program demonstrated superior glycemic control compared to insulin and single-receptor GLP-1 agonists across multiple phase 3 studies
• SURMOUNT-1 trial reported that 85-91% of participants in the treatment groups achieved 5% or greater weight reduction
• SURPASS-3 MRI sub-study showed liver fat reductions of 29.8% to 47.1% compared to 11.2% with insulin degludec at 52 weeks
• Post-hoc analyses demonstrated improvements in systolic and diastolic blood pressure, total cholesterol, LDL cholesterol, and triglyceride levels
• Research indicates preferential reduction in fat mass with relative preservation of lean mass in body composition studies

Areas of Research Interest

Why Researchers Are Investigating This Compound

This compound has attracted significant research attention in the following areas. These represent active fields of scientific inquiry, not validated therapeutic claims. No medical benefits are stated or implied.

• Enhanced weight management: the dual-receptor mechanism of action has attracted significant research attention for its novel approach to metabolic regulation
• Body composition research: studies suggesting preferential fat mass reduction with lean mass preservation have generated significant interest among body composition researchers
• Liver fat research: investigations into hepatic lipid metabolism in clinical sub-studies have drawn interest from liver disease researchers
• Next-generation metabolic research: as a dual-agonist, it represents an evolution beyond single-target GLP-1 compounds and has become a benchmark in incretin research

Published Research

Peer-Reviewed References

1. Dahl D, Onishi Y, Norwood P, et al. "Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction." Cardiovascular Diabetology (2022). doi:10.1186/s12933-022-01604-7
2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine (2022). doi:10.1056/NEJMoa2206038
3. Frias JP, Davies MJ, Rosenstock J, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes." New England Journal of Medicine (2021). doi:10.1056/NEJMoa2107519
4. Sattar N, McGuire DK, Pavo I, et al. "Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program." Cardiovascular Diabetology (2024). doi:10.1186/s12933-024-02147-9